MOTS-c is a real mitochondrial peptide, but its benefits are shown in mice, not people. Old mice given it for 2 weeks ran 2.16-fold farther; in humans, exercise raises natural MOTS-c, but no randomized trial shows that injecting it helps.[3] It is not FDA-approved, and there are no long-term human safety data.[5]
MOTS-c is one of the more scientifically interesting peptides being sold in the “research” longevity market — and one of the most overstated. It is a genuine mitochondrial-derived peptide with a real, well-characterized role in metabolic regulation, discovered in academic laboratories and studied in respectable journals. But almost all of that evidence sits in mice and cell culture. The claims you will see attached to it — that it boosts metabolism, sharpens exercise capacity and extends healthy lifespan in people — are extrapolations from animal data, not findings from human outcome trials. Both halves of that sentence are true at once, and keeping them separate is the whole point.
What is MOTS-c?
MOTS-c (“mitochondrial open reading frame of the twelve-S rRNA type-c”) is a short peptide encoded within mitochondrial DNA — a member of a small family of mitochondrial-derived peptides that also includes humanin. It was identified and characterized in a 2015 study showing that this 12–16 amino-acid peptide promotes metabolic homeostasis and, in mice, reduces obesity and insulin resistance.[1] Mechanistically, MOTS-c is best understood as a metabolic regulator that targets the folate–AICAR–AMPK pathway, nudging cells toward the kind of energy-sensing signaling associated with caloric restriction and exercise. That is real, mechanistically grounded biology — it is the reason the peptide is taken seriously by mitochondrial researchers, and it is worth stating clearly before the caveats.
The preclinical biology is genuinely interesting
Several independent lines of work, almost all in rodents or cells, point in a consistent direction. In the original discovery work, MOTS-c improved insulin sensitivity and protected against diet-induced obesity in mice.[1] A later mechanistic study reported that MOTS-c regulates circulating plasma metabolites and enhances insulin sensitivity, reinforcing the metabolic-regulator framing.[2] And in a widely cited 2021 study, MOTS-c behaved as an exercise-induced, mitochondrially encoded regulator of age-dependent physical decline and muscle homeostasis — MOTS-c treatment improved physical performance and counteracted age-related decline in mice: after 2 weeks of daily injections, old mice ran 2-fold longer and 2.16-fold farther, and 17% vs 0% of old mice (treated vs untreated) reached the final, fastest stage of the treadmill test. The human component was limited to expression data rather than a clinical outcome trial: in sedentary young men (n = 10), one session of hard cycling raised MOTS-c in muscle 11.9-fold and in blood about 1.5-fold, with blood levels back to baseline 4 hours later.[3] Taken together, this is a credible mechanistic story: a mitochondrial peptide that rises with exercise and influences metabolic and muscle aging in model organisms.
Does MOTS-c work in humans?
Here is the part the marketing skips. Essentially every supportive efficacy result above comes from animal models or cell systems. There are no adequately powered, randomized, placebo-controlled human trials demonstrating that injecting MOTS-c improves body composition, athletic performance, healthspan or lifespan in people. The human data that exist are largely observational — MOTS-c is detectable in human blood, its levels change with exercise and tend to fall with age, and its expression varies across populations — which is interesting biology but is a long way from showing that supplementing it does anything beneficial and safe. Reviews of the mitochondrial-derived peptide field are candid that, despite the promise, these molecules remain early-stage and their therapeutic translation to humans is unproven.[4] A peptide that moves a pathway in a mouse, or that correlates with fitness in a cohort, has not been shown to be a treatment in humans — and MOTS-c has not crossed that line. This is the recurring shape of the endogenous-longevity-molecule story: the aging-suppressor protein klotho has an even stronger animal and genetic-association case, and still nothing a consumer can actually take.
What are the side effects of MOTS-c?
Nobody can give a reliable side-effect list for MOTS-c, because no controlled human trial has recorded one. When the FDA reviewed it for pharmacy compounding, the agency wrote that it had not identified any human exposure data on drug products containing MOTS-c by any route, that it may pose a significant risk of immune reactions (immunogenicity) for some routes, and that peptide-related impurities complicate its characterization.[5] Online anecdotes are not the same as a measured safety profile.
Is MOTS-c FDA-approved or legal to compound?
MOTS-c is not FDA-approved for any use. In the FDA's interim compounding policy it sat in Category 2 (substances that may present significant safety risks) until its nomination was withdrawn; the FDA now lists it under “bulk drug substances nominated but withdrawn” (page current as of April 22, 2026).[5] That is not a clearance: MOTS-c is not on the 503A bulks list, so a pharmacy cannot lawfully compound it from bulk. On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee discussed adding MOTS-c to that list for obesity and osteoporosis,[6] and the panel voted 7-5, with 2 abstentions, to recommend it.[7] The vote is non-binding: the FDA must still decide whether to accept it and then go through notice-and-comment rulemaking before compounding would be allowed.[7]
The unregulated-supply problem
MOTS-c is not an approved drug for any of the uses it is sold for. It reaches consumers almost entirely as a “research-use-only” injectable from suppliers that are not held to pharmaceutical manufacturing standards. That means the actual identity, dose, purity and sterility of what is in a given vial are unverified — problems that sit on top of the absence of human efficacy and long-term safety data, not instead of it. Stimulating metabolic and AMPK signaling is also not automatically benign, and no controlled long-term human safety dataset exists for repeated MOTS-c administration. This is the same structural issue that shadows the rest of the injectable “research peptide” market; see our broader read on peptides marketed for weight loss and on NAD+ precursors, where promising mechanism similarly outruns proven human benefit.
The honest bottom line
MOTS-c is the rare longevity peptide where the underlying science is genuinely worth respecting: it is a real mitochondrial-derived peptide, it engages a plausible metabolic pathway, and the rodent data on insulin sensitivity and exercise capacity are interesting enough to justify continued research. But “promising biology” and “proven human therapeutic” are different categories, and MOTS-c is firmly in the first. Until there are real randomized human trials — not mouse studies, not correlations — the longevity and performance claims are extrapolation, and the product itself is an unregulated injectable of unverified contents. The appropriate posture is curiosity about the science and skepticism about the sales pitch.